PMID- 28524050
OWN - NLM
STAT- MEDLINE
DCOM- 20180412
LR  - 20180412
IS  - 1952-4013 (Electronic)
IS  - 1167-1122 (Linking)
VI  - 27
IP  - 3
DP  - 2017 Jun 1
TI  - Cutaneous adverse effects during ipilimumab treatment for metastatic melanoma: a 
      prospective study.
PG  - 266-270
LID - 10.1684/ejd.2017.3023 [doi]
AB  - Ipilimumab is an immunomodulatory antibody directed against cytotoxic 
      T-lymphocyte-associated antigen 4 (CTLA-4), which is administered to patients 
      with advanced melanoma, with a proven positive effect on overall survival. The 
      cutaneous adverse effects (AEs) of ipilimumab are relatively frequent, although 
      described as usually mild and rarely life threatening. To describe a three-year 
      experience of a single institute in detecting and managing cutaneous AEs. A 
      cohort of patients (n = 41) treated with ipilimumab (3 mg/kg/three weeks) for 
      metastatic melanoma, from 2013 to 2016, was investigated for adverse cutaneous 
      events. On dermatological evaluation, 34.1% of the patients in our series 
      developed cutaneous AEs: rash (7.3%; n = 3), folliculitis (7.3%; n = 3), 
      mucositis (2.4%; n = 1), rosacea (2.4%; n = 1), eczema (2.4%; n = 1), acneiform 
      eruption (2.4%; n = 1), syringometaplasia mucinosa (2.4%; n = 1), Stevens-Johnson 
      syndrome (2.4%; n = 1), and vitiligo (4.9%; n = 2). These were all Grade 1 and 2 
      AEs, except for the case of Stevens-Johnson syndrome (Grade 4). On a 
      patient-reported scale, 4.9% (n = 2) and 9.8% (n = 4) of the patients complained 
      of severe xerosis and pruritus, respectively. Ipilimumab was relatively well 
      tolerated in our series, mainly causing mild cutaneous AEs, which, in our 
      experience, responded satisfactorily to conventional therapies. Only in one case 
      was the treatment discontinued, due to Grade 4 side effects.
FAU - Dika, Emi
AU  - Dika E
AD  - Dermatology, Department of Experimental, Diagnostic and Specialty Medicine, 
      University of Bologna, Bologna, Italy.
FAU - Ravaioli, Giulia Maria
AU  - Ravaioli GM
AD  - Dermatology, Department of Experimental, Diagnostic and Specialty Medicine, 
      University of Bologna, Bologna, Italy.
FAU - Fanti, Pier Alessandro
AU  - Fanti PA
AD  - Dermatology, Department of Experimental, Diagnostic and Specialty Medicine, 
      University of Bologna, Bologna, Italy.
FAU - Piraccini, Bianca Maria
AU  - Piraccini BM
AD  - Dermatology, Department of Experimental, Diagnostic and Specialty Medicine, 
      University of Bologna, Bologna, Italy.
FAU - Lambertini, Martina
AU  - Lambertini M
AD  - Dermatology, Department of Experimental, Diagnostic and Specialty Medicine, 
      University of Bologna, Bologna, Italy.
FAU - Chessa, Marco Adriano
AU  - Chessa MA
AD  - Dermatology, Department of Experimental, Diagnostic and Specialty Medicine, 
      University of Bologna, Bologna, Italy.
FAU - Baraldi, Carlotta
AU  - Baraldi C
AD  - Dermatology, Department of Experimental, Diagnostic and Specialty Medicine, 
      University of Bologna, Bologna, Italy.
FAU - Ribero, Simone
AU  - Ribero S
AD  - Department of Medical Sciences, Section of Dermatology, University of Turin, 
      Turin, Italy.
FAU - Andrea, Ardizzoni
AU  - Andrea A
AD  - Oncology Medical Unit; Department of Oncology and Haematology, University of 
      Bologna, Bologna, Italy.
FAU - Melotti, Barbara
AU  - Melotti B
AD  - Oncology Medical Unit; Department of Oncology and Haematology, University of 
      Bologna, Bologna, Italy.
FAU - Patrizi, Annalisa
AU  - Patrizi A
AD  - Dermatology, Department of Experimental, Diagnostic and Specialty Medicine, 
      University of Bologna, Bologna, Italy.
LA  - eng
PT  - Journal Article
PL  - France
TA  - Eur J Dermatol
JT  - European journal of dermatology : EJD
JID - 9206420
RN  - 0 (Antineoplastic Agents, Immunological)
RN  - 0 (Ipilimumab)
SB  - IM
MH  - Antineoplastic Agents, Immunological/*adverse effects
MH  - Drug Eruptions/drug therapy/*etiology
MH  - Humans
MH  - Ipilimumab/*adverse effects
MH  - Melanoma/*drug therapy/pathology
MH  - Neoplasm Metastasis
MH  - Prospective Studies
MH  - Pruritus/chemically induced/drug therapy
MH  - Skin Neoplasms/*drug therapy/pathology
OTO - NOTNLM
OT  - adverse events
OT  - ipilimumab
OT  - melanoma
OT  - treatment
EDAT- 2017/05/20 06:00
MHDA- 2018/04/13 06:00
CRDT- 2017/05/20 06:00
PHST- 2017/05/20 06:00 [pubmed]
PHST- 2018/04/13 06:00 [medline]
PHST- 2017/05/20 06:00 [entrez]
AID - ejd.2017.3023 [pii]
AID - 10.1684/ejd.2017.3023 [doi]
PST - ppublish
SO  - Eur J Dermatol. 2017 Jun 1;27(3):266-270. doi: 10.1684/ejd.2017.3023.